Month: November 2019

Top 20

Top Biosimilar Companies with Approved and Pipeline Products in the

Biosimilars are the key alternatives for expensive Biologics therapies and saving millions of dollars of patients spent in the treatment of multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. The companies are focusing on […]Read More

DigiHealth

AstraZeneca Collaborates with JVP to Invest in Digital Health Program

Shots: AstraZeneca launches its digital health program, BeyondBio with the initial investment of $2.8M AstraZeneca in collaborates with JVP to support Israeli start-up companies by providing direct access to databases and leading academic research institutes in digital health with an aim to find technological solutions in the medical sphere The digital health program is operated […]Read More

Regulatory

AstraZeneca Reports the US FDA Acceptance of sBLA and Granted

Shots: The sBLA is based P-III CASPIAN study assessing Imfinzi + SOC (etoposide with either cisplatin or carboplatin)/ Imfinzi + tremelimumab + CT vs CT as monothx. in patients with previously untreated extensive-stage SCLC in 200+ centers across 23 countries The P-III CASPIAN study demonstrated improvement in OS (13.0 cs 10.3 mos.) with a reduction […]Read More

Pharma

WuXi ATU and GeneMedicine Collaborate to Develop and Manufacture Oncolytic

Shots: WuXi ATU to provide overall process development, viral bank manufacturing, viral stock characterization and cGMP commercial manufacturing and IND filing services via its Oncolytic Virus CDMO platform, to accelerate the development and commercialization of Gene Medicine’s oncolytic virus products The collaboration allows GeneMedicine to advance its pipeline products from the clinical stage to commercialization […]Read More

Regulatory

Roche’s Kadcyla (trastuzumab emtansine) Receives Health Canada’s Approval for The

Shots: The approval is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as adjuvant therapy in people with HER2+ eBC with pathological residual invasive disease in the breast and/or axillary lymph nodes following neoadjuvant taxane and Herceptin-based treatment The P-III KATHERINE study results: reduction in the risk of residual invasive BC recurrence or death […]Read More

Insights+

Octavus Consulting Collaborates with IBCI for Delivering of Professional Educational

Shots: The IBCI educational programs will focus on providing perspectives on Business & Competitive Intelligence role in every industry for professionals from all domains in India. Additionally, IBCI has already provided 50 types of programs for 7000+ highly qualified professionals from every domain Octavus Consulting with its team expertise in Competitive Intelligence and Product Strategies […]Read More